Targeted Protein Degradation Platforms

Profacgen's targeted protein degradation platforms provide comprehensive, modular solutions for selective elimination of disease-relevant proteins through proteasome, lysosome, and autophagy pathways, enabling therapeutic strategies beyond traditional inhibition.

Conventional small-molecule inhibitors often fail to address undruggable targets or suffer from incomplete pathway suppression and compensatory resistance. Targeted protein degradation offers a fundamentally different mechanism: induced proximity to cellular degradation machinery, resulting in catalytic target elimination rather than transient occupancy.

Profacgen has established a multi-pathway degradation platform encompassing proteolysis-targeting chimeras (PROTACs), lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), and autophagosome-tethering compounds (ATTECs), alongside conditional and tag-based systems. This integrated approach enables rational selection of the optimal degradation modality based on target localization, pathway biology, and therapeutic objectives.

Overview of Targeted Protein Degradation Platforms

Targeted protein degradation harnesses endogenous cellular machinery to selectively eliminate proteins of interest. The major degradation pathways and systems include:

• Proteasome-mediated degradation: The ubiquitin-proteasome system (UPS) degrades intracellular proteins tagged with polyubiquitin chains. PROTACs and related modalities recruit E3 ligases to induce proximity-dependent ubiquitination and subsequent 26S proteasomal degradation
• Lysosome-mediated degradation: The endosomal-lysosomal pathway degrades membrane-bound and extracellular proteins through receptor-mediated endocytosis. LYTACs bridge target proteins to cell-surface lysosome-targeting receptors (e.g., CI-M6PR, ASGPR) for internalization and lysosomal proteolysis
• Autophagy-mediated degradation: Macroautophagy engulfs cytoplasmic cargo into autophagosomes for lysosomal degradation. AUTACs introduce K63-linked ubiquitin tags to recruit autophagy receptors, while ATTECs directly tether targets to autophagosome membrane proteins (LC3) via small-molecule bridges
• Conditional degradation systems: Destabilization domains (DDs) and tag-based technologies (e.g., HaloTag, dTAG) enable small-molecule-inducible, reversible protein degradation with temporal and dose-dependent control, supporting target validation and mechanistic studies

Figure 1. Overview of proteasomal and lysosomal degradation. (Zhao et al., 2022)

Our Platform Technologies

Profacgen offers a comprehensive suite of targeted protein degradation technologies, each optimized for specific target classes and cellular contexts:

Comparison of Degradation Modalities

Selection of the optimal degradation platform depends on target localization, pathway biology, and therapeutic requirements. The following comparison guides modality selection:

Platform Selection Strategy

Profacgen employs a structured decision framework to match your target and program objectives with the optimal degradation modality:

• Target localization assessment: Intracellular soluble proteins are directed toward PROTAC, AUTAC, or hydrophobic tag platforms; membrane and secreted proteins are channeled to LYTAC; aggregates and large assemblies are matched with ATTEC or AUTAC
• Pathway feasibility analysis: Evaluation of E3 ligase expression, autophagy flux capacity, and lysosomal function in the target cell type or tissue context
• Reversibility and control requirements: Conditional systems (DD, HaloPROTAC) are selected for target validation and essential gene studies; irreversible modalities are preferred for therapeutic applications
• Chemical tractability: Assessment of target druggability, ligand availability, and linker optimization potential for heterobifunctional molecule design

Applications

Our targeted protein degradation platforms support diverse therapeutic and research applications:

• Oncology: Degradation of oncogenic kinases (BCR-ABL, EGFR), transcription factors (BRD4, STAT3), and immune checkpoint proteins to overcome resistance and expand the druggable target space
• Neurodegenerative Diseases: Clearance of protein aggregates (tau, α-synuclein, TDP-43) and misfolded proteins via autophagy-activating modalities, addressing the root pathology of Alzheimer's, Parkinson's, and ALS
• Inflammation: Targeted elimination of pro-inflammatory cytokines, signaling kinases (IRAK4, RIPK1), and inflammasome components to achieve durable anti-inflammatory effects with reduced systemic toxicity
• Undruggable Targets: Degradation of transcription factors, scaffold proteins, and non-enzymatic regulatory proteins that lack conventional catalytic active sites or deep binding pockets

Why Choose Profacgen

Related Services

• Protein Degrader Discovery Service
• Ligand Discovery and Design Service
• Small Molecule Ligands Screening
• Peptide Design for E3 Ligase or Target
• Custom Peptide and Compound Synthesis
• Novel E3 Ligase Discovery
• E3 Ligase Activity Assay
• E3 Ligase or Target Proteins Expression
• Custom Protein Ubiquitination Service
• Protein Degrader in Vitro Evaluation

References:

1. Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Sig Transduct Target Ther. 2022;7(1):113. doi:10.1038/s41392-022-00966-4
2. Buckley DL, Raina K, Darricarrere N, et al. HaloPROTACs: use of small molecule PROTACs to induce degradation of halotag fusion proteins. ACS Chem Biol. 2015;10(8):1831-1837. doi:10.1021/acschembio.5b00442
3. Xin L, Wang H, Yang M, et al. Hydrophobic tagging: A promising paradigm for targeted protein degradation. Cell Insight. 2026;5(1):100295. doi:10.1016/j.cellin.2025.100295